Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mathematical Model Predicts Erythrocyte Lifespan

By LabMedica International staff writers
Posted on 02 Dec 2010
A mathematical model has been developed reflecting how red blood cells (RBCs) change in size and hemoglobin content during their four-month lifespan.

It appears that erythrocytes from healthy individuals are cleared from the bloodstream before they shrink beyond a specific size. More...
However, in patients with mild iron-deficiency anemia or in genetic conditions such as thalassemia, RBCs continue shrinking past the clearance threshold for healthy cells.

A collaboration between a physician at Massachusetts General Hospital (MGH, Boston, MA, USA) and a mathematician from Harvard University (Cambridge, MA, USA), has led to the development of the mathematical model. The investigators worked to develop a relatively simple mathematical description of how the volume and hemoglobin content of the average RBC change over time. Starting from the known characteristics of young and mature cells, they developed equations that approximate how the young cells are transformed into mature cells. After building their model with data from healthy individuals, they discovered that data from patients with three types of anemia correspond to different parameter values in the model.

The investigators were able to predict the development of iron-deficiency anemia, when they saw an increasing population of small erythrocytes in blood samples from individuals who had a normal blood test and then went on to develop iron-deficiency anemia 30 to 90 days later. A good deal is known about how these cells initially develop from blood-system stem cells, but much less is known about how RBCs mature and are eventually destroyed. Recent studies have revealed that very young RBCs, which are larger and have higher hemoglobin levels than mature cells, experience a rapid loss in size and hemoglobin content during their first few days. As the cells mature, they continue to lose both volume and hemoglobin, but at significantly slower rates.

John Higgins, M.D., a physician at MGH, said, "Unexplained iron-deficiency anemia in adults is often a sign of a much more serious disorder. One study showed that 11% of those with iron-deficiency anemia not caused by obvious bleeding actually had colon cancer. In cases like those, diagnosing anemia 90 days earlier would be comparable to diagnosing the underlying cancer 90 days sooner." The study was published online on November 8, 2010, in Proceedings of the [US] National Academy of Science (PNAS) early edition.

Related Links:
Massachusetts General Hospital
Harvard University


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.